Evidence map›Paper›PMID 41156021›Full record

ReviewJournal of clinical medicine2025

Definition, Incidence, Prediction, and Prevention of Bleeding Events After Transcatheter Aortic Valve Implantation.

Iosif Xenogiannis, Ioannis Lianos, Grigoris V Karamasis, Charalampos Varlamos, Fotios Kolokathis, Christos Pappas, Stamatia Kovra, Konstantinos Tsaousidis, Christos Mourmouris, Antonis N Pavlidis and 2 more

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Iosif XenogiannisDepartment of Cardiology, Mitera General Hospital, Hygeia HealthCare Group, 15123 Athens, Greece.
Ioannis LianosDepartment of Cardiology, Mitera General Hospital, Hygeia HealthCare Group, 15123 Athens, Greece.ORCID 0000-0003-2677-8657
Grigoris V KaramasisSecond Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0002-4560-7629
Charalampos VarlamosSecond Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0002-5795-3377
Fotios KolokathisSecond Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Christos PappasSecond Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Stamatia KovraDepartment of Cardiology, Mitera General Hospital, Hygeia HealthCare Group, 15123 Athens, Greece.
Konstantinos TsaousidisAbbott, 17456 Athens, Greece.
Christos MourmourisDepartment of Cardiology, Mitera General Hospital, Hygeia HealthCare Group, 15123 Athens, Greece.
Antonis N PavlidisDepartment of Cardiology, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK.
Andreas S TriantafyllisDepartment of Cardiology, Asklepion General Hospital, 11528 Athens, Greece.ORCID 0000-0002-8037-463X
Andreas S KalogeropoulosDepartment of Cardiology, Mitera General Hospital, Hygeia HealthCare Group, 15123 Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bleeding remains the most common complication following transcatheter aortic valve implantation (TAVI), despite a decline in its incidence over time. Periprocedural (≤30 days) major or life-threatening bleeding is reported to occur in 2.0-6.6% of patients undergoing TAVI. Major bleeding events carry a significant risk of mortality, with rates of 14.1% at 30 days and 27.8% at one year. The timely identification and management of patients at an elevated risk are therefore essential. Preventive measures include optimizing antithrombotic therapies, utilizing ultrasound-guided femoral access, employing single arterial access or a radial artery for secondary access, and administering unfractionated heparin under close monitoring. Long-term follow-up is essential for recognizing and managing late hemorrhages. In this review, we aimed to provide an in-depth analysis of bleeding events associated with TAVI and the most recent updates regarding the antithrombotic therapy of TAVI patients and its clinical impact.

Indexed as

anticoagulationantiplateletsbleedingcomputed tomographyfemoral accesstranscatheter aortic valve implantation (TAVI)ultrasound guidance

Identifiers

PMID41156021
PMCPMC12565270

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.